We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-3.05%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$52.7B
AUM Growth
-$2.48B
(-4.5%)
Cap. Flow
+$256M
Cap. Flow
% of AUM
0.49%
Top 10 Holdings %
Top 10 Hldgs %
16.27%
Holding
2,367
New
187
Increased
1,008
Reduced
966
Closed
158
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$237M |
| 2 |
Pfizer
PFE
|
+$200M |
| 3 |
Moderna
MRNA
|
+$143M |
| 4 |
EPAM Systems
EPAM
|
+$106M |
| 5 |
Gilead Sciences
GILD
|
+$94.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Target
TGT
|
+$138M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$135M |
| 3 |
AngloGold Ashanti
AU
|
+$112M |
| 4 |
Costco
COST
|
+$111M |
| 5 |
Microsoft
MSFT
|
+$111M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.94% |
| 2 | Healthcare | 15.7% |
| 3 | Industrials | 11.74% |
| 4 | Financials | 11.69% |
| 5 | Consumer Discretionary | 10.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2101
Oramed Pharmaceuticals
ORMP
$177M
| $155K | ﹤0.01% |
17,954
-2,021
| -10% | -$20.7K |
|
2102
First Bank
FRBA
$458M
| $152K | ﹤0.01% |
10,687
-1,342
| -11% | -$19.3K |
|
2103
Veru
VERU
$44.8M
| $149K | ﹤0.01% |
3,095
+724
| +31% | +$39.3K |
|
2104
NeoGenomics
NEO
$2.12B
| $147K | ﹤0.01% |
12,098
-1,562
| -11% | -$32.9K |
|
|
HT
2105
DELISTED
Hersha Hospitality Trust Priority Class A Common Shares of Beneficial Interest
HT
| $147K | ﹤0.01% |
+16,234
| New | +$150K |
|
2106
MannKind Corp
MNKD
$1.23B
| $145K | ﹤0.01% |
39,517
-9,760
| -20% | -$35.7K |
|
2107
Humacyte
HUMA
$191M
| $143K | ﹤0.01% |
+20,279
| New | +$118K |
|
|
CMRX
2108
DELISTED
Chimerix, Inc.
CMRX
| $143K | ﹤0.01% |
31,181
-28,914
| -48% | -$161K |
|
2109
Ocular Therapeutix
OCUL
$2.14B
| $141K | ﹤0.01% |
28,395
+6,675
| +31% | +$37K |
|
2110
Lifetime Brands
LCUT
$221M
| $139K | ﹤0.01% |
10,801
-3,527
| -25% | -$49.1K |
|
|
KG
2111
Kestrel Group
KG
$68.8M
| $139K | ﹤0.01% |
2,893
-219
| -7% | -$11.5K |
|
2112
Globalstar
GSAT
$10.8B
| $137K | ﹤0.01% |
6,228
-9,766
| -61% | -$166K |
|
2113
Evolus
EOLS
$551M
| $136K | ﹤0.01% |
12,145
-115,608
| -90% | -$985K |
|
|
INN
2114
Summit Hotel Properties
INN
$651M
| $135K | ﹤0.01% |
+13,546
| New | +$133K |
|
2115
Rush Street Interactive
RSI
$2.91B
| $134K | ﹤0.01% |
+18,437
| New | +$186K |
|
2116
Aemetis
AMTX
$123M
| $133K | ﹤0.01% |
10,496
-3,954
| -27% | -$43.6K |
|
2117
Akebia Therapeutics
AKBA
$240M
| $132K | ﹤0.01% |
184,465
+102,691
| +126% | +$220K |
|
2118
Viking Therapeutics
VKTX
$3.94B
| $132K | ﹤0.01% |
+43,925
| New | +$158K |
|
2119
Alto Ingredients
ALTO
$323M
| $129K | ﹤0.01% |
+18,918
| New | +$106K |
|
|
HARP
2120
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $126K | ﹤0.01% |
2,533
-416
| -14% | -$21.6K |
|
2121
Opendoor
OPEN
$3.48B
| $124K | ﹤0.01% |
+14,855
| New | +$138K |
|
2122
Q32 Bio
QTTB
$459M
| $123K | ﹤0.01% |
+2,243
| New | +$139K |
|
|
AMTI
2123
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
| $119K | ﹤0.01% |
+15,853
| New | +$131K |
|
2124
FuelCell Energy
FCEL
$1.54B
| $118K | ﹤0.01% |
685
-2,971
| -81% | -$471K |
|
2125
Mistras Group
MG
$591M
| $118K | ﹤0.01% |
17,903
-3,801
| -18% | -$25.9K |
|
Similar funds
VGA
AQR Capital Management's Q1 2022 Portfolio in Review
As of Q1 2022, AQR Capital Management held 2,367 positions worth $52.7B, down 4.5% from $55.2B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
AQR Capital Management's Q1 2022 filing shows 187 new, 1,008 increased, 966 reduced and 158 closed positions. Its largest new stake was Carnival Corporation Ltd: 1,737,168 shares worth $34.8M. The largest sale was Target, an estimated $138M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 24% a quarter earlier, followed by Healthcare and Industrials.
- AQR Capital Management's largest Q1 2022 buy was Carnival Corporation Ltd: 1,737,168 shares worth $34.8M.
- AQR Capital Management added most to Meta Platforms (Facebook) in Q1 2022, an estimated $237M increase.
- AQR Capital Management's biggest Q1 2022 reduction was Target, cutting an estimated $138M.
- AQR Capital Management fully exited Xilinx Inc in Q1 2022, selling an estimated $25.4M.
- AQR Capital Management's ten largest holdings make up 16% of its $52.7B portfolio in Q1 2022.
- AQR Capital Management opened 187 new positions and closed 158 in Q1 2022.
- AQR Capital Management's portfolio value fell 4.5% quarter-over-quarter to $52.7B.
Based on AQR Capital Management's 13F filing for Q1 2022, filed 16 May 2022.